

www.ilts.org

From Medical Treatment to Liver Transplantation

PROGRAM



**NAFLD/NASH
CONSENSUS
CONFERENCE** **2018**

VENICE | ITALY

FEBRUARY 15, 2018



INTERNATIONAL LIVER
TRANSPLANTATION SOCIETY



**NAFLD/NASH
CONSENSUS
CONFERENCE 2018**

VENICE | ITALY
FEBRUARY 15, 2018



INTERNATIONAL LIVER TRANSPLANTATION SOCIETY

Course Directors

Patrizia Burra, MD, PhD

University of Padova
Padova, Italy

Marina Berenguer, MD

University and Polytechnic La Fe Hospital
Valencia, Spain

Objectives

This conference will provide a detailed overview of the current challenges and advances in prevention, early diagnosis and treatment of NAFLD/NASH. It will focus on various issues concerning both adult and pediatric populations, including lifestyle, new drugs, and surgery, from mild liver disease to advanced chronic liver disease, and including candidates both during liver transplant and in the post-transplant setting.

International experts will convene to focus on NAFLD/NASH management strategies and best practices in a consensus conference format.

The consensus conference proceedings will be used to generate a Practice Guidelines manuscript for publication in *Transplantation*. The conference will focus on six separate areas:

1. **Epidemiology and prevention**
2. **Medical treatment: lifestyle changes and pharmacological therapy**
3. **Risk of hepatocellular carcinoma: surveillance and management**
4. **End stage liver disease and liver transplantation**
5. **Management of recurrent and de novo NAFLD/NASH after liver transplantation**
6. **Pediatric population**



**NAFLD/NASH
CONSENSUS
CONFERENCE 2018**

VENICE | ITALY
FEBRUARY 15, 2018



INTERNATIONAL LIVER TRANSPLANTATION SOCIETY

Educational Goals

The overall goal of this course is to discuss the increasing incidence of NAFLD and NASH and metabolic syndrome in U.S., Europe and Asia and how NAFLD/NASH represent an increasing indication to liver transplantation.

It will focus on the most recent advances and discuss the potential of new drugs to prevent the progression of steatosis to fibrosis and the role of liver transplantation for advanced liver disease.

Learning objectives

Understand who are the groups at risk of developing NAFLD/NASH.

Identify strategies for preventive interventions.

Understand how to manage patients at risk to develop hepatic steatosis and steato-fibrosis.

Understand how new drugs can be used in patients with steatosis.

Understand how to perform surveillance for hepatocellular carcinoma in this special populations at higher risk to develop tumors.

Evaluate how co-morbidities (cardiovascular, hypertension, diabetes, dyslipidemia, obesity, renal dysfunction...) should be assessed and treated in the candidate to liver transplantation.

Understand what are the modifiable risk factors for recurrent and de novo NAFLD/NASH after liver transplantation.

Learn the utility of targeted immunosuppression therapy in patients at risk to develop NAFLD/NASH after transplantation.

Understand the different management of risk factors of NAFLD/NASH development in pediatric population and if medical treatment differs from the adult population.



NAFLD/NASH CONSENSUS CONFERENCE 2018

VENICE | ITALY
FEBRUARY 15, 2018



INTERNATIONAL LIVER TRANSPLANTATION SOCIETY

Introductory Lectures

- 08:30 - 09:00 Why NASH? Because HCV is disappearing?
09:00 - 09:30 Are we also eliminating HCV in special populations?

Consensus Conference Lectures

- 09:30 - 10:00 Epidemiology and prevention
10:00 - 10:30 Medical treatment: life style changes and pharmacological therapy
10:30 - 11:00 Risk of hepatocellular carcinoma: surveillance and management
11:00 - 11:30 Coffee break
11:30 - 12:00 End stage liver disease and liver transplantation
12:00 - 12:30 Management of recurrent and de novo NAFLD/NASH after liver transplantation
12:30 - 13:00 Pediatric population
13:00 - 13:30 Discussion
13:30 - 14:00 Lunch break

Afternoon Working Groups

- 14:00 - 15:30 Epidemiology and prevention
 Medical treatment: life style changes and pharmacological therapy
 Risk of hepatocellular carcinoma: surveillance and management
 End stage liver disease and liver transplantation
 Management of recurrent and de novo NAFLD/NASH after liver transplantation
 Pediatric population
15:30 - 16:00 Coffee break
16:00 - 18:00 Working Groups' presentations with statements
18:00 - 18:30 Summary

-
- 19:30 - 21:00 Faculty Dinner



NAFLD/NASH CONSENSUS CONFERENCE 2018

VENICE | ITALY
FEBRUARY 15, 2018



INTERNATIONAL LIVER TRANSPLANTATION SOCIETY

ILTS Headquarters

K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin
Germany
Phone: +49 (0) 30 24603 349
Fax: +49 (0) 30 24603 200
ilts@ilts.org
www.ilts.org

Conference Venue:

San Servolo Residential and Study Centre
Isola di San Servolo n. 1
30124 Venice

sanservolo.servizimetroplitani.ve.it/en/congresses

Phone: + 39 041 2765001

Fax: +39 041 276 5402

E-Mail: congressi@servizimetroplitani.ve.it

Session Room:

Sala Teatro, Room 2, Room 3,
Room 4, Room 6, Room 7, Room 8

Registration

Please register online by 12 February 2018,
23:59 CET (GMT+2)

Should you require further assistance please don't
hesitate to contact the ILTS Registration Department:

ilts-consensusregistration@kit-group.org

Hotline: +49 30 24603 410

Accommodation at venue hotel:

All participants are responsible for their own
accommodation. The Conference organizers have
reserved a limited contingent of rooms in advance
for attendees at the venue hotel. Please contact the
hotel and let them know that you wish to book a
room out of the contingent.

To book a room, please fill in the
[Accommodation Form](#) and send it
to the following E-Mail address:
reception@servizimetroplitani.ve.it

Reservation hotline: + 39 041 2765001

Alternative accommodation:

Please visit the official Venice Hotel website for
further choices: www.venicehotel.com

ILTS acknowledges the generous support of the following companies: **Gilead & Novartis.**